HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibition of intravascular mouse melanoma dissemination by recombinant human interferon alpha A/D.

Abstract
The effects of pure recombinant human interferon alpha A/D (IFN alpha A/D) on natural killer (NK) activity and the experimental lung metastasis of B16-F10 melanoma were studied. Treatment of C57BL/6 mice with IFN alpha A/D augmented splenic NK activity and also inhibited the experimental lung metastasis of B16-F10 melanoma in a dose-dependent manner. The augmentation of NK activity and the inhibition of experimental lung metastasis by IFN alpha A/D were completely abolished in anti-asialo GM1-pretreated mice. These results suggested that the effector cells which inhibited melanoma metastasis in the present system were mainly NK cells, and that it was by activating NK cells that IFN alpha A/D had its effect. We next studied the timing of IFN alpha A/D administration for the most effective prevention of melanoma metastasis. The inhibitory effect of IFN alpha A/D was most pronounced when it was given 12 hr before or at the same time as melanoma inoculation. This suggested that melanoma cells were susceptible to NK cells only for a short period of time after intravascular invasion.
AuthorsT Yokoyama, O Yoshie, H Aso, T Ebina, N Ishida
JournalJapanese journal of cancer research : Gann (Jpn J Cancer Res) Vol. 77 Issue 1 Pg. 80-4 (Jan 1986) ISSN: 0910-5050 [Print] Japan
PMID3082819 (Publication Type: Journal Article)
Chemical References
  • Glycosphingolipids
  • Interferon Type I
  • Recombinant Proteins
  • G(M1) Ganglioside
  • asialo GM1 ganglioside
Topics
  • Animals
  • G(M1) Ganglioside
  • Glycosphingolipids (immunology)
  • Interferon Type I (pharmacology, therapeutic use)
  • Killer Cells, Natural (immunology)
  • Lung Neoplasms (secondary)
  • Macrophages (immunology)
  • Male
  • Melanoma (immunology, pathology, therapy)
  • Mice
  • Mice, Inbred C57BL
  • Neoplastic Cells, Circulating
  • Recombinant Proteins
  • Spleen (immunology)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: